Cargando…

Immune efficacy of five novel recombinant Bordetella bronchiseptica proteins

BACKGROUND: The Gram-negative pathogen Bordetella bronchiseptica causes acute and chronic respiratory infection in a variety of animals. Currently, there is no vaccine to prevent these infections. To identify useful candidate antigens for such a vaccine, five B. bronchiseptica genes including amino...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yan, Chen, Hui, Wei, Qiang, Xiao, Chenwen, Ji, Quanan, Bao, Guolian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520013/
https://www.ncbi.nlm.nih.gov/pubmed/26223229
http://dx.doi.org/10.1186/s12917-015-0488-4
_version_ 1782383596897566720
author Liu, Yan
Chen, Hui
Wei, Qiang
Xiao, Chenwen
Ji, Quanan
Bao, Guolian
author_facet Liu, Yan
Chen, Hui
Wei, Qiang
Xiao, Chenwen
Ji, Quanan
Bao, Guolian
author_sort Liu, Yan
collection PubMed
description BACKGROUND: The Gram-negative pathogen Bordetella bronchiseptica causes acute and chronic respiratory infection in a variety of animals. Currently, there is no vaccine to prevent these infections. To identify useful candidate antigens for such a vaccine, five B. bronchiseptica genes including amino acid ATP-binding cassette transporter substrate-binding protein (ABC), lipoprotein (PL), outer membrane porin protein (PPP), leu/ile/val-binding protein (BPP), and conserved hypothetical protein (CHP) were cloned and the recombinant proteins were expressed. The immune responses of mice to vaccination with individual recombinant proteins were measured. RESULTS: Each of the tested recombinant proteins induced a high antibody titer. PPP and PL showed protective indices against challenges with B. bronchiseptica. The protection ratios were 62.5 and 50 %, respectively, compared with 12.5 % for control vaccinations. The protection ratios of ABC, BPP, and CHP were not significantly different from the controls. IgG-subtype and cytokine analysis demonstrated that PPP and PL can induce two immune responses: a humoral immune response and a cell-mediated immune response. The humoral immunity-mediated, Th2-type response dominated. CONCLUSION: The identification of PPP and PL, which offer immune-protective potential, identifies them as candidates for the development of a diagnostic test or a vaccine for B. bronchiseptica.
format Online
Article
Text
id pubmed-4520013
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45200132015-07-31 Immune efficacy of five novel recombinant Bordetella bronchiseptica proteins Liu, Yan Chen, Hui Wei, Qiang Xiao, Chenwen Ji, Quanan Bao, Guolian BMC Vet Res Research Article BACKGROUND: The Gram-negative pathogen Bordetella bronchiseptica causes acute and chronic respiratory infection in a variety of animals. Currently, there is no vaccine to prevent these infections. To identify useful candidate antigens for such a vaccine, five B. bronchiseptica genes including amino acid ATP-binding cassette transporter substrate-binding protein (ABC), lipoprotein (PL), outer membrane porin protein (PPP), leu/ile/val-binding protein (BPP), and conserved hypothetical protein (CHP) were cloned and the recombinant proteins were expressed. The immune responses of mice to vaccination with individual recombinant proteins were measured. RESULTS: Each of the tested recombinant proteins induced a high antibody titer. PPP and PL showed protective indices against challenges with B. bronchiseptica. The protection ratios were 62.5 and 50 %, respectively, compared with 12.5 % for control vaccinations. The protection ratios of ABC, BPP, and CHP were not significantly different from the controls. IgG-subtype and cytokine analysis demonstrated that PPP and PL can induce two immune responses: a humoral immune response and a cell-mediated immune response. The humoral immunity-mediated, Th2-type response dominated. CONCLUSION: The identification of PPP and PL, which offer immune-protective potential, identifies them as candidates for the development of a diagnostic test or a vaccine for B. bronchiseptica. BioMed Central 2015-07-30 /pmc/articles/PMC4520013/ /pubmed/26223229 http://dx.doi.org/10.1186/s12917-015-0488-4 Text en © Liu et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Liu, Yan
Chen, Hui
Wei, Qiang
Xiao, Chenwen
Ji, Quanan
Bao, Guolian
Immune efficacy of five novel recombinant Bordetella bronchiseptica proteins
title Immune efficacy of five novel recombinant Bordetella bronchiseptica proteins
title_full Immune efficacy of five novel recombinant Bordetella bronchiseptica proteins
title_fullStr Immune efficacy of five novel recombinant Bordetella bronchiseptica proteins
title_full_unstemmed Immune efficacy of five novel recombinant Bordetella bronchiseptica proteins
title_short Immune efficacy of five novel recombinant Bordetella bronchiseptica proteins
title_sort immune efficacy of five novel recombinant bordetella bronchiseptica proteins
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520013/
https://www.ncbi.nlm.nih.gov/pubmed/26223229
http://dx.doi.org/10.1186/s12917-015-0488-4
work_keys_str_mv AT liuyan immuneefficacyoffivenovelrecombinantbordetellabronchisepticaproteins
AT chenhui immuneefficacyoffivenovelrecombinantbordetellabronchisepticaproteins
AT weiqiang immuneefficacyoffivenovelrecombinantbordetellabronchisepticaproteins
AT xiaochenwen immuneefficacyoffivenovelrecombinantbordetellabronchisepticaproteins
AT jiquanan immuneefficacyoffivenovelrecombinantbordetellabronchisepticaproteins
AT baoguolian immuneefficacyoffivenovelrecombinantbordetellabronchisepticaproteins